Wall Street analysts expect that Laboratory Co. of America Holdings (NYSE:LH) will report earnings of $2.41 per share for the current fiscal quarter, according to Zacks Investment Research. Ten analysts have made estimates for Laboratory Co. of America Holdings’ earnings, with the highest EPS estimate coming in at $2.53 and the lowest estimate coming in at $2.32. Laboratory Co. of America Holdings reported earnings of $2.15 per share in the same quarter last year, which suggests a positive year over year growth rate of 12.1%. The company is expected to announce its next quarterly earnings report on Thursday, February 15th.

On average, analysts expect that Laboratory Co. of America Holdings will report full year earnings of $9.52 per share for the current year, with EPS estimates ranging from $9.42 to $9.59. For the next fiscal year, analysts expect that the business will report earnings of $10.40 per share, with EPS estimates ranging from $10.02 to $10.70. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Laboratory Co. of America Holdings.

Laboratory Co. of America Holdings (NYSE:LH) last posted its quarterly earnings results on Wednesday, October 25th. The medical research company reported $2.46 EPS for the quarter, beating the consensus estimate of $2.38 by $0.08. Laboratory Co. of America Holdings had a return on equity of 12.07% and a net margin of 6.91%. The firm had revenue of $2.60 billion during the quarter, compared to analysts’ expectations of $2.55 billion. During the same quarter in the prior year, the firm posted $2.25 EPS. The company’s revenue for the quarter was up 9.5% on a year-over-year basis.

Several equities research analysts have recently weighed in on the company. Zacks Investment Research lowered Laboratory Co. of America Holdings from a “buy” rating to a “hold” rating in a research note on Friday, October 27th. Robert W. Baird reiterated a “hold” rating and issued a $150.00 price objective on shares of Laboratory Co. of America Holdings in a research note on Friday, October 27th. Barclays PLC upped their price objective on Laboratory Co. of America Holdings from $183.00 to $190.00 and gave the company an “overweight” rating in a research note on Thursday, October 26th. Deutsche Bank AG upped their price objective on Laboratory Co. of America Holdings from $170.00 to $172.00 and gave the company a “buy” rating in a research note on Thursday, October 26th. Finally, Craig Hallum reiterated a “buy” rating and issued a $180.00 price objective (up from $175.00) on shares of Laboratory Co. of America Holdings in a research note on Thursday, October 26th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $169.00.

WARNING: This piece was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/09/2-41-eps-expected-for-laboratory-co-of-america-holdings-lh-this-quarter.html.

In other Laboratory Co. of America Holdings news, Director R Sanders Williams sold 3,100 shares of the stock in a transaction on Friday, August 11th. The stock was sold at an average price of $156.88, for a total value of $486,328.00. Following the transaction, the director now directly owns 10,073 shares in the company, valued at approximately $1,580,252.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David P. King sold 132,713 shares of the stock in a transaction on Tuesday, September 5th. The shares were sold at an average price of $157.06, for a total value of $20,843,903.78. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 212,971 shares of company stock worth $33,378,333. 0.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Swiss National Bank boosted its position in Laboratory Co. of America Holdings by 1.9% in the 2nd quarter. Swiss National Bank now owns 460,275 shares of the medical research company’s stock valued at $70,947,000 after buying an additional 8,500 shares during the last quarter. Sentry Investments Corp. boosted its position in Laboratory Co. of America Holdings by 29.6% in the 2nd quarter. Sentry Investments Corp. now owns 924,900 shares of the medical research company’s stock valued at $142,564,000 after buying an additional 211,180 shares during the last quarter. Allen Investment Management LLC boosted its position in Laboratory Co. of America Holdings by 13.7% in the 2nd quarter. Allen Investment Management LLC now owns 732,798 shares of the medical research company’s stock valued at $112,953,000 after buying an additional 88,564 shares during the last quarter. Taylor Asset Management Inc. boosted its position in Laboratory Co. of America Holdings by 1.8% in the 2nd quarter. Taylor Asset Management Inc. now owns 51,600 shares of the medical research company’s stock valued at $7,953,000 after buying an additional 900 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its position in Laboratory Co. of America Holdings by 2.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 39,891 shares of the medical research company’s stock valued at $6,150,000 after buying an additional 881 shares during the last quarter. Hedge funds and other institutional investors own 93.84% of the company’s stock.

Laboratory Co. of America Holdings (NYSE LH) traded up $0.31 during mid-day trading on Monday, hitting $152.10. The stock had a trading volume of 585,635 shares, compared to its average volume of 707,266. Laboratory Co. of America Holdings has a 52 week low of $119.51 and a 52 week high of $164.22. The company has a market cap of $15,513.30, a price-to-earnings ratio of 16.39, a P/E/G ratio of 1.62 and a beta of 0.87. The company has a debt-to-equity ratio of 1.18, a quick ratio of 1.75 and a current ratio of 1.89.

About Laboratory Co. of America Holdings

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD).

Get a free copy of the Zacks research report on Laboratory Co. of America Holdings (LH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Laboratory Co. of America Holdings (NYSE:LH)

Receive News & Stock Ratings for Laboratory Co. of America Holdings Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America Holdings and related stocks with our FREE daily email newsletter.